The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a […]
New Drug Offers Hope to Millions With Severe Migraines Read More »
Migraine and genetic Migraine is associated with a polygenic inheritance Migraines and genetic: A new study has found that some families are especially sensitive to Migraines and that genetics influences the type of migraine suffered by affected people. Migraine is a disease that has as its main symptom headache, throbbing, unilateral, accompanied by nausea or
Migraine and genetic Read More »
Findings from a new study conducted in rats reveal that females may be more susceptible to migraines and less responsive to treatment because of the way fluctuations in the hormone estrogen affect cells in the brain. Of the more than 38 million Americans who experience migraine headaches, 28 million are women. Compared to men, women
Potential source of gender differences in migraines Read More »
The largest patient online event in the world for headache returns this April 18-26.
The Migraine World Summit will bring together over 30 top experts, doctors and specialists to share new treatments, research and strategies for migraine and chronic headache. It is available to anyone with an internet connection.
AGENDA Migraine World Summit 2018 Read More »
The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed new measures to avoid exposure of babies to valproate medicines in the womb, because exposed babies are at high risk of malformations and developmental problems. The new measures include a ban on the use of such medicines for migraine or bipolar
New measures to avoid valproate exposure in pregnancy Read More »
Our General Assembly [GA] and the 1 st Migraine and Headache International Patient Advocacy Summit [MHIPAS], which will be held between Thursday, May 10 th and Sunday, May 13 th , at the NH Schiphol Airport Hotel, Amsterdam, Netherlands.
Migraine and Headache International patient Advocacy Summit (MHIPAS) Read More »
Exploratory Research into effect of Migraine in the workplace : This research develops on existing information, providing a deeper and wider spectrum of understanding into the effect of migraines. Reasons why employees choose to be present or absent, how triggers and symptoms can be managed, perceived human capital value, and possible spill overs from the
Migraine in the workplace: research Read More »
As we all have suffered once in our life from a “headache”, it is common to think that headache and migraine, are more or less, the same, and together we have reached the vulgarization of this disease that generates a true social misunderstanding of migreneurs. Now, what would you think of a disease that affects
People with migraine spend 2 years of their life in bed Read More »
On the 24 of January 2018, from 10.00 to 12:00, will be celebrated inside the European Parliament (Room ASP A3F383) a meeting focused on: “Making Visible The Invisible On Headache Pain: Sharing Successful Experiences Across Europe”. Register here for the 24 of January 2018. The initiative is promoted by Active Citizenship Network in partnership with the European Headache Alliance (EMHA), and it will
Making Visible The Invisible On Headache Pain Read More »
Laboratory-made antibody Erenumab blocks neural brain pathway and is first new treatment for attacks approved in 20 years A new migraine drug that can halve the length of time sufferers are laid low by the debilitating condition has been hailed as an “incredibly important” advance. Erenumab, a laboratory-made antibody that blocks a neural brain pathway
New Migraine drug hailed as “Incredibly important” breakthrough Read More »
